Cardiovascular disease is the leading cause of death in Australia. Aliskiren is the first renin inhibitor-type drug to be approved for clinical use for treatment of hypertension. The aim of this project is to evaluate the effectiveness of aliskiren for the treatment of heart attack and heart failure, as compared to existing therapies. Aliskiren may potentially replace or complement current therapies, thereby reducing death and improving health and economic benefits for the community.
The prevalence of liver cirrhosis worldwide is rising due. The majority of the morbidity and mortality, which arises with cirrhosis, occurs due to the development of portal hypertension. In cirrhosis unexplained vasodilatation of the splanchnic circulation occurs contributing significantly to portal hypertension. I expect to confirm through my experiments that the ACE2/Ang 1-7/Mas axis (alternate RAS) is responsible for this vasodilatation and that antagonists targeting this system may have a ro ....The prevalence of liver cirrhosis worldwide is rising due. The majority of the morbidity and mortality, which arises with cirrhosis, occurs due to the development of portal hypertension. In cirrhosis unexplained vasodilatation of the splanchnic circulation occurs contributing significantly to portal hypertension. I expect to confirm through my experiments that the ACE2/Ang 1-7/Mas axis (alternate RAS) is responsible for this vasodilatation and that antagonists targeting this system may have a role in therapy.Read moreRead less
Interactions Between Neuropeptide FF Receptor And Hypothalamic Neuropeptides In The Regulation Of Energy Homeostasis And Obesity
Funder
National Health and Medical Research Council
Funding Amount
$95,733.00
Summary
Despite the alarming obesity epidemic, there currently exists no effective long-term treatment for obesity. Neuropeptide FF and its receptor NPFF2R have an emerging role in regulating food intake and body fat stores. Results from this study will show whether NPFF2R plays an important role in regulating appetite, metabolic rate, body weight and fat stores, thus help to identify whether NPFF2R-targeted therapeutics would confer significant benefit for the long-term treatment of obesity.
How Does Fampridine Affect Upper Limb Function In Multiple Sclerosis?
Funder
National Health and Medical Research Council
Funding Amount
$113,237.00
Summary
Multiple sclerosis (MS) is a common and disabling neurological disease affecting thousands of young Australians. In 2011 Fampridine received TGA approval for walking impairment in MS, but its mechanism of action is unknown and its effects on domains other than lower limb function remain untested. Our study will test whether Fampridine improves upper limb impairment in MS patients and will use electrophysiological measures of central nervous system conduction to uncover its mechanism of action.
Investigating Role Of Insulin Resistance And Sympathetic Nervous System In Metabolic Features Of PCOS
Funder
National Health and Medical Research Council
Funding Amount
$150,468.00
Summary
PCOS affects 9-18% of Australian reproductive aged women. Whilst reproductive features are prominent, PCOS has major psychological and metabolic consequences. Emerging data implicate the involvement of the sympathetic nervous system in PCOS. The aim of this PhD is to investigate the role of the sympathetic nervous system in insulin resistance and other metabolic features of PCOS and determine whether modification of this system's activity will favorably influence the metabolic consequences assoc ....PCOS affects 9-18% of Australian reproductive aged women. Whilst reproductive features are prominent, PCOS has major psychological and metabolic consequences. Emerging data implicate the involvement of the sympathetic nervous system in PCOS. The aim of this PhD is to investigate the role of the sympathetic nervous system in insulin resistance and other metabolic features of PCOS and determine whether modification of this system's activity will favorably influence the metabolic consequences associated with PCOS.Read moreRead less
The Adaptive Immune Response To Epstein-Barr Virus.
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
Epstein-Barr virus (EBV), the causative agent of glandular fever, is carried by a large proportion of adults worldwide. EBV is known to cause many cancers including Burkitt's lymphoma and has been linked to autoimmune diseases such as multiple sclerosis. The aim of this project is to find new fragments of EBV that the body's immune system can recognise and use to protect itself against the virus. Once found these pieces will form parts of the puzzle that will one day combine as a vaccine against ....Epstein-Barr virus (EBV), the causative agent of glandular fever, is carried by a large proportion of adults worldwide. EBV is known to cause many cancers including Burkitt's lymphoma and has been linked to autoimmune diseases such as multiple sclerosis. The aim of this project is to find new fragments of EBV that the body's immune system can recognise and use to protect itself against the virus. Once found these pieces will form parts of the puzzle that will one day combine as a vaccine against EBV.Read moreRead less